» Articles » PMID: 35456341

Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with Constipation-Randomized Case-Control Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Apr 23
PMID 35456341
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: Irritable bowel syndrome (IBS) is a common disease, with multiple pathophysiological mechanisms involved. A single treatment for all the patients with IBS is not possible. Prebiotics may have a beneficial effect on IBS patients with constipation. (2) Methods: A randomized cross-over case-control study was conducted, including patients with IBS and constipation (IBS-C), who were randomized into two groups receiving a specific constipation diet with or without a food supplement containing inulin, choline and silymarin (Stoptoxin®, Fiterman Pharma, Iasi, Romania). Patients were evaluated at baseline, after four and eight weeks, using a questionnaire to assess IBS symptoms. (3) Results: 51 IBS-C patients were included, of which 47 patients finished the trial (33 women, mean age 52.82 years). Adding Stoptoxin® to a diet for constipation brought extra benefits. Abdominal pain severity improved by 68.3% after the diet and Stoptoxin® (p = 0.004) and abdominal bloating severity parameter improved by 34.8% (p = 0.040). The stool number per week and the stool consistency according to the Bristol scale were improved, but without statistical significance between groups (p > 0.05). (4) Conclusions: The combination of inulin, choline and silymarin associated with a specific-constipation diet had obvious clinical beneficial effects on IBS-C patients in terms of bowel movement, abdominal pain and bloating.

Citing Articles

Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.

Napolitano M, Fasulo E, Ungaro F, Massimino L, Sinagra E, Danese S Microorganisms. 2023; 11(10).

PMID: 37894027 PMC: 10609453. DOI: 10.3390/microorganisms11102369.


Global Trends in Research of Pain-Gut-Microbiota Relationship and How Nutrition Can Modulate This Link.

Lu G, Zhang S, Wang R, Zhang Z, Wang W, Wen Q Nutrients. 2023; 15(17).

PMID: 37686738 PMC: 10490108. DOI: 10.3390/nu15173704.


Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.

Di Rosa C, Altomare A, Terrigno V, Carbone F, Tack J, Cicala M Nutrients. 2023; 15(7).

PMID: 37049488 PMC: 10096616. DOI: 10.3390/nu15071647.

References
1.
Wagner H . Multitarget therapy--the future of treatment for more than just functional dyspepsia. Phytomedicine. 2006; 13 Suppl 5:122-9. DOI: 10.1016/j.phymed.2006.03.021. View

2.
Chong P, Chin V, Looi C, Wong W, Madhavan P, Yong V . The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol. 2019; 10:1136. PMC: 6579922. DOI: 10.3389/fmicb.2019.01136. View

3.
Shorey S, Demutska A, Chan V, Siah K . Adults living with irritable bowel syndrome (IBS): A qualitative systematic review. J Psychosom Res. 2020; 140:110289. DOI: 10.1016/j.jpsychores.2020.110289. View

4.
Sturkenboom R, Keszthelyi D, Brandts L, Weerts Z, Snijkers J, Masclee A . The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome. Qual Life Res. 2021; 31(4):1209-1221. PMC: 8960586. DOI: 10.1007/s11136-021-02995-y. View

5.
Arias N, Arboleya S, Allison J, Kaliszewska A, Higarza S, Gueimonde M . The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. Nutrients. 2020; 12(8). PMC: 7468957. DOI: 10.3390/nu12082340. View